HANSOH PHARMA Receives NMPA Breakthrough Therapy Designation for HS-20093-Adebrelimab Combo in Advanced NSCLC

Bulletin Express

Yesterday

Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy designation to the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 when used in combination with adebrelimab.

According to the April 16 2026 filing, the proposed indication covers patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) lacking actionable genomic alterations whose disease has progressed or relapsed following platinum-based chemotherapy.

The designation is expected to expedite clinical development and review timelines for HS-20093 plus adebrelimab, reflecting unmet medical need in this patient segment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182628144"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182628144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182628144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182628144","market":"hk","top_or_hot":-1,"title":"HANSOH PHARMA Receives NMPA Breakthrough Therapy Designation for HS-20093-Adebrelimab Combo in Advanced NSCLC","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy designation to the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 when used in combination with adebrelimab.</p>\n<p>According to the April 16 2026 filing, the proposed indication covers patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) lacking actionable genomic alterations whose disease has progressed or relapsed following platinum-based chemotherapy.</p>\n<p>The designation is expected to expedite clinical development and review timelines for HS-20093 plus adebrelimab, reflecting unmet medical need in this patient segment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA Receives NMPA Breakthrough Therapy Designation for HS-20093-Adebrelimab Combo in Advanced NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA Receives NMPA Breakthrough Therapy Designation for HS-20093-Adebrelimab Combo in Advanced NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-16 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy designation to the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 when used in combination with adebrelimab.</p>\n<p>According to the April 16 2026 filing, the proposed indication covers patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) lacking actionable genomic alterations whose disease has progressed or relapsed following platinum-based chemotherapy.</p>\n<p>The designation is expected to expedite clinical development and review timelines for HS-20093 plus adebrelimab, reflecting unmet medical need in this patient segment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1182628144","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182628144","pubTimestamp":1776339868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy designation to the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"翰森制药HS-20093-Adebrelimab组合治疗晚期非小细胞肺癌获NMPA突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough-Therapy designation to the company’s self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 when used in combination with adebrelimab.\nAccording to the April 16 2026 filing, the proposed indication covers patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) lacking actionable genomic alterations whose disease has progressed or relapsed following platinum-based chemotherapy.\nThe designation is expected to expedite clinical development and review timelines for HS-20093 plus adebrelimab, reflecting unmet medical need in this patient segment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}